SCHEMBL15540280

SCHEMBL15540280

CC(C)(F)CN1CCC(COc2ccc(-c3ccc(C(=O)N4CCCC4C(N)=O)nc3)cc2F)CC1

nearest known ligand 0.45

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 7/20 0.45
DGAT1 O75907 11/20 0.41
SCN9A Q15858 1/20 0.39
WNT1 P04628 1/20 0.38
DYRK1A Q13627 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15539372 1.00 CNR2 (0.45) CNR2DGAT1SCN9AWNT1DYRK1A
SCHEMBL15539745 0.90 CNR2 (0.43) CNR2DGAT1
SCHEMBL16777086 0.90 CNR2 (0.43) CNR2DGAT1
SCHEMBL16803737 0.89 CNR2 (0.40) CNR2SCN9A
SCHEMBL15539790 0.87 CNR2 (0.44) CNR2DGAT1SCN9A
SCHEMBL15539082 0.87 CNR2 (0.44) CNR2DGAT1SCN9A
SCHEMBL16803848 0.87 CNR2 (0.41) CNR2
SCHEMBL16803851 0.87 CNR2 (0.41) CNR2SCN9A
SCHEMBL16803852 0.87 CNR2 (0.41) CNR2SCN9A
SCHEMBL16803849 0.87 CNR2 (0.41) CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2858986-B1 PIPERIDINE DERIVATIVES AS GPR119 AGONISTS CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2019-10-30 EP claimed
US-9944600-B2 Piperidine derivatives for GPR119 agonist CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2018-04-17 US claimed
US-20150166480-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2015-06-18 US claimed
EP-2858986-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST Chong Kun Dang Pharmaceutical Corp. (KR) 2015-04-15 EP claimed
WO-2013187646-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2013-12-19 WO claimed
EP-2858986-B1 PIPERIDINE DERIVATIVES AS GPR119 AGONISTS CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2019-10-30 EP disclosed
US-9944600-B2 Piperidine derivatives for GPR119 agonist CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2018-04-17 US disclosed
US-20150166480-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2015-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166480-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST GPR119, FFAR2, GPR84 CNR2 42/4885DGAT1 819/4885SCN9A 746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.